Het forum is in alleen-lezen modus.

Inhoud voormalig Psorinovo Forum (01 aug 2018)

Het complete forum van de Vereniging Psorinovo is hier terug te vinden (2011-2018). Er kan hier niet meer op de postings gereageerd worden. Als je toch iets zou willen zeggen, plaats dan een nieuw bericht in het nieuwe psoriasispatientennederland.nl/forumc met een link naar het bericht in dit oude forum.

Artikel Nieboer over Dimethylfumaraat.

  • Jim
  • Jim's Profielfoto Onderwerp Auteur
  • Offline
  • Administrator
  • Administrator
3 jaren 11 maanden geleden - 3 jaren 11 maanden geleden #1885 door Jim
Jim heeft een nieuw onderwerp gemaakt: Artikel Nieboer over Dimethylfumaraat.
Al een oud artikel, maar het geeft in een notendop weer wat er nog steeds geldt en waarvan veel dermatologen de ins- en outs in relatie tot Psorinovo niet kennen.

Journal of the American Academy of Dermatology
Volume 20, Issue 4, April 1989, Pages 601–608
Systemic therapy with fumaric acid derivates: New possibilities in the treatment of psoriasis
• C. Nieboera, ,
• D. de Hoopb,
• A.C. van Loenenc,
• P.N.J. Langendijkc,
• E. van Dijka

For the past two decades fumaric acid (FA) therapy has become an increasingly popular treatment in Western Europe for psoriasis. FA therapy originally was developed by Schweckendiek and subsequently standardized, by Schäfer. Schäfer's fumaric acid compound therapy (FACT) consists of the oral intake of dimethylfumaric acid ester (DMFAE) and several salts of monoethylfurnaric acid ester (MEFAE) in combination with topical fumaric acid therapy (1% to 3% MEFAE in an ointment or FA in bathing oils) and a diet. Schäfer claimed excellent results in a large number of patients. Preliminary studies by German dermatologists, however, revealed contradictory therapeutic results and serious side effects, and FA treatment was soon abandoned by dermatologists. To assess, the value of FA therapy we conducted an open pilot study of 36 patients in which FACT therapy appeared to be rather effective. Thereafter, several controlled studies with MEFAE sodium in two different dosages versus placebo, and DMFAE versus placebo, were done. The results indicated that MEFAE sodium in dosages up to 240 mg daily was ineffective, whereas daily dosages of 720 mg resulted in a significant decrease in scaling and itching but did not affect extension of the eruption, DMFAE, 240 mg daily, produced a significant amelioration and prevented extension. Side effects of FA treatment were nausea, diarrhea, general malaise, and severe stomachache. Mild disturbances of liver and kidney function during treatment were observed with the 720 mg dosage of MEFAE and with the 240 mg dosage of DMFAE. Moreover, a relative lymphopenia with a selective decrease of suppressor T lymphocytes occurred in about 50% of the patients treated with DMFAE. Although oral therapy with FA derivatives has to be considered experimental, it may be a new possibility in the systemic treatment of psoriasis.

Reprint requests; C. Nieboer, PhD, Department of Dermatology, Free University Hospital, Postbus 7057, 1007 MB Amsterdam, The Netherlands.
a From the Department of Dermatology, Free University Hospital, Amsterdam.
b From the Department of Clinical Pharmacy, Free University Hospital, Amsterdam.
c Stichting Ziekenhuisvoorzieningen Gelderse Vallei, Ede-Bennekom.
Copyright © 1989 Published by Mosby, Inc.

GPG/PGP Fingerprint: A306 E7D0 C1B7 A09B 78A3 E8B3 E44F 88EE A502 9544
Laatst bewerkt: 3 jaren 11 maanden geleden door Jim.